Multi-CAR T Cell Therapy for Acute Myeloid Leukemia

Sponsor
Shenzhen Geno-Immune Medical Institute
Study ID
NCT03222674
Phase
PHASE1/PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
2 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells — BIOLOGICAL
    Infusion of Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells

Study Details

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of multi-CAR T cell therapy targeting different AML surface antigens in patients with relapsed or refractory acute myeloid leukemia (AML). Another goal of the study is to learn more about the function of the multi-CAR T cells and their persistency in the patients.

Key Dates

First listed
Jul 19, 2017
Start date
Dec 31, 2026
Status verified
Aug 2026
Primary completion
Jun 30, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Single arm
    CAR T cells to treat AML

Primary Outcome Measure

percentage of patients with treatment related adverse effect [ Time Frame: a year ]

Central Contacts

Find similar trials

Nationwide
Leukemia (other) trialsOncology trialsBlood cancer trials

Related Studies